Suzhou, China, November 5, 2026 — The team led by Professor Bin Cao of China-Japan Friendship Hospital recently published online in The Lancet Infectious Diseases (2025 impact factor: 29.4), a top-tier international journal in infectious diseases, the latest research findings entitled “Imipenem-cilastatin-funobactam versus imipenem-cilastatin-relebactam in patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia: a phase 3, double-blind, non-inferiority randomised trial.” This is the first phase 3 clinical trial (the REITAB-2 study) to evaluate the efficacy and safety of the novel β-lactam/β-lactamase inhibitor combination (BL/BLI) imipenem/cilastatin/funobactam (IMI/FUN) in adult patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
HABP/VABP are major types of hospital-acquired infections and rank among the types associated with the highest fatality rates in hospital settings[1]. In the current etiology of HABP in Chinese general hospitals, Acinetobacter baumannii accounts for 16.2%–35.8% of cases, Pseudomonas aeruginosa for 16.9%–22%, and Klebsiella pneumoniae for 8.3%–15.3%[1]; in VABP, the proportion of Acinetobacter baumannii is even higher, reaching 35.7%–50%[1]. More alarmingly, carbapenem resistance among these pathogens has shown an overall upward trend: carbapenem-resistant Acinetobacter baumannii (CRAB) accounts for as much as 60%–70%[1], carbapenem-resistant Pseudomonas aeruginosa (CRPA) for 20%–40%[1], and carbapenem-resistant Klebsiella pneumoniae (CRKP) has risen from 3% in 2005 to 22%–25% at present[2, 3]. The threat of drug-resistant infections is severe, yet treatment options that effectively cover these key resistant pathogens remain very limited, and patients urgently need new therapeutic tools.
It was precisely against this backdrop of unmet clinical need that the phase 3 study evaluating the novel β-lactamase inhibitor combination IMI/FUN for the treatment of HABP/VABP was designed, with its urgency and clinical significance being self-evident. The REITAB-2 study demonstrated that IMI/FUN was non-inferior to IMI/REL with respect to 14-day all-cause mortality in patients with HABP/VABP, with a favorable safety and tolerability profile. This novel BL/BLI provides a valuable additional treatment option for patients with severe Gram-negative pneumonia. Given funobactam's broad-spectrum β-lactamase inhibitory activity, including coverage of the class D enzymes commonly found in Acinetobacter baumannii, IMI/FUN is expected to expand treatment options in regions with high carbapenem resistance prevalence.
Mr. Meijie Le, Chief Executive Officer of Evopoint Bio, commented: “Congratulate Professor Bin Cao and his team on the publication of their latest research findings in The Lancet Infectious Diseases. This is the highest-impact-factor academic journal in which results from a registrational clinical study of a China-developed antimicrobial drug have ever been published, underscoring the strong recognition of China's innovative anti-infective drug development achievements by a top-tier international academic platform. Antimicrobial resistance has become a major public health issue in China and globally. Imipenem-cilastatin-funobactam for injection is China's first self-developed novel BL/BLI (β-lactamase inhibitor combination) that comprehensively covers CRAB, CRKP, and CRPA, and it holds immense clinical value.”
About Imipenem-cilastatin-funobactam
Imipenem-cilastatin-funobactam is a novel β-lactamase inhibitor combination independently developed by Evopoint Bio, comprising the company's self-developed β-lactamase inhibitor funobactam (XNW4107) in combination with imipenem/cilastatin sodium. It is intended for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Gram-negative bacteria. With a broad spectrum of antimicrobial activity, the product covers the three major carbapenem-resistant Gram-negative pathogens — carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), and carbapenem-resistant Pseudomonas aeruginosa (CRPA) — directly addressing the core challenges of current clinical anti-infective therapy. The New Drug Application (NDA) for this product was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in July 2025. Earlier, the product had successively received the Qualified Infectious Disease Product (QIDP) designation and Fast Track designation (FTD) from the U.S. FDA, reflecting international recognition of its R&D quality and clinical value.
References
[1] 中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志, 2018, 41(4): 255-280. DOI:10.3760/cma.j.issn.1001-0939.2018.04.006.
[2] Hu Fupin et al. Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET Antimicrobial Resistance Surveillance Program, 2024. DOI:10.16718/j.1009-7708.2025.06.002.
[3] Qin X, Ding L, Hao M, et al. Antimicrobial resistance of clinical bacterial isolates in China: current status and trends[J]. JAC Antimicrob Resist, 2024, 6(2): dlae052. DOI:10.1093/jacamr/dlae052.
